First line CLL combo to provide "significant benefit to patients," says Roche

As the dust settles on this year’s annual meeting of the American Society of Clinical Oncology (ASCO), analysts have a lot of promising data to digest.

Not least, clinical updates related to 17 different medicines presented over the course of the Chicago-based congress by Swiss pharma giant Roche (ROG: SIX).

Roche’s Thomas Buechele tells The Pharma Letter: “This year, we are excited about data in breast cancer, lung cancer, hematological cancers as well as our tumor agnostic treatment approach with entrectinib.”